UNSPSC 51373432: Chlorpheniramine/hydrocodone/phenindamine/phenylephrine/pyrilamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE301. This VA Drug Class (RE301) classifies this compound as belonging to the group OPIOID-CONTAINING ANTITUSSIVES/EXPECTORANTS.

UNSPSC 51373432 Chlorpheniramine/hydrocodone/phenindamine/phenylephrine/pyrilamine is a Commodity code that in recent state and local solicitations represents procurement of generic multi-source pharmaceuticals and OTC products distributed across participating government facilities, as well as specialized health-support items such as naloxone and drug deactivation systems. State and local buyers under this code include county health departments, state purchasing offices coordinating multi-jurisdictional cooperative purchasing programs, and regional health systems. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, exemplifies the scale of activity — it coordinates pharmaceutical procurement across state and local government facilities including Oregon, requiring vendors to supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencara, Cardinal Health 110 and 112, and Morris & Dickson Co., LLC) and certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act.

Florida and Minnesota represent the most recent geographic activity. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023 and a two-year initial term plus one-year renewal option. MMCAP's RFP S1070000015802, posted January 20, 2026 with a response deadline of March 26, 2026, establishes multiple contracts for generic multi-source pharmaceuticals and OTC products; vendors must submit detailed product information including National Drug Codes, demonstrate pricing flexibility through flat-price, net-price, or WAC-minus formats, and maintain contractual relationships with at least two of the three authorized wholesalers. Both solicitations require E-Verify compliance and specific insurance coverage, and MMCAP explicitly evaluates proposals on price competitiveness (75 percent weight), fixed pricing for contract term (10 percent), EDI capability (5 percent), administrative-fee compliance (5 percent), and administrative-format requirements (5 percent).